imported>Brinkery |
imported>Brinkery |
| Line 1: |
Line 1: |
| === <span class="mw-headline" id="Kalkulierte_Therapie.5B1.5D.5B2.5D" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"font-size:13.5pt;\nmso-fareast-font-family:\"Times New Roman\";mso-bidi-font-family:Calibri;\nmso-bidi-theme-font:minor-latin;mso-ansi-language:DE"}" style="box-sizing: inherit; font-size: 13.5pt;">Kalkulierte Therapie</span><sup id="cite_ref-:0_1-2" class="reference" style="box-sizing: inherit; font-size: 19.2px; line-height: 1; position: relative; vertical-align: baseline; top: -0.5em; unicode-bidi: isolate; white-space: nowrap;">[[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20note-%3A0-1|[1]]]</sup><sup id="cite_ref-:1_2-1" class="reference" style="box-sizing: inherit; font-size: 19.2px; line-height: 1; position: relative; vertical-align: baseline; top: -0.5em; unicode-bidi: isolate; white-space: nowrap;">[[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20note-%3A1-2|[2]]]</sup></span> === | | ===<span class="mw-headline" id="Kalkulierte_Therapie.5B1.5D.5B2.5D" style="box-sizing: inherit;"><span class="ve-pasteProtect" data-ve-attributes="{"style":"font-size:13.5pt;\nmso-fareast-font-family:\"Times New Roman\";mso-bidi-font-family:Calibri;\nmso-bidi-theme-font:minor-latin;mso-ansi-language:DE"}" style="box-sizing: inherit; font-size: 13.5pt;">Kalkulierte Therapie</span></span><ref>Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael Scheld W, van de Beek D, Bleck TP, Garton HJ, Zunt JR: 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017; 64: e34–e65</ref><ref>Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter, AWMF-Registernummer: 030/089 [<nowiki>https://www.awmf.org/leitlinien/detail/ll/030-089.html</nowiki></ref>=== |
| Vancomycin PLUS Meropenem | | Vancomycin PLUS Meropenem |
|
| |
|
| Line 6: |
Line 6: |
| Alternative Vancomycin: Linezolid (cave: bakteriostatisch) | | Alternative Vancomycin: Linezolid (cave: bakteriostatisch) |
| <br /> | | <br /> |
| | | <br /><span class="reference-text" style="box-sizing: inherit;"><span data-ve-attributes="{"style":"mso-ansi-language:DE"}" style="box-sizing: inherit;"><span class="ve-pasteprotect" style="box-sizing: inherit;"></span></span></span> |
| # <span class="mw-cite-backlink" style="box-sizing: inherit; user-select: none;">↑ <sup style="box-sizing: inherit; font-size: 13.2px; line-height: 1; position: relative; vertical-align: baseline; top: -0.5em;">[[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-%3A0%201-0|<span class="cite-accessibility-label" style="box-sizing: inherit; user-select: none; top: -99999px; clip: rect(1px, 1px, 1px, 1px); overflow: hidden; position: absolute !important; padding: 0px !important; border: 0px !important; height: 1px !important; width: 1px !important;">Hochspringen nach:</span>1,0]][[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-%3A0%201-1|1,1]][[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-%3A0%201-2|1,2]][[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-%3A0%201-3|1,3]]</sup></span> <span class="reference-text" style="box-sizing: inherit;"><span style="color: rgb(51, 51, 51)">28. <span class="ve-pasteprotect" style="box-sizing: inherit;"><span data-ve-attributes="{"style":"mso-tab-count:1"}" style="box-sizing: inherit;"> <span style="box-sizing: inherit;"> </span></span></span>Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael Scheld W, van de Beek D, Bleck TP, Garton HJ, Zunt JR: 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017; 64: e34–e65</span></span>
| |
| # <span class="mw-cite-backlink" style="box-sizing: inherit; user-select: none;">↑ <sup style="box-sizing: inherit; font-size: 13.2px; line-height: 1; position: relative; vertical-align: baseline; top: -0.5em;">[[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-%3A1%202-0|<span class="cite-accessibility-label" style="box-sizing: inherit; user-select: none; top: -99999px; clip: rect(1px, 1px, 1px, 1px); overflow: hidden; position: absolute !important; padding: 0px !important; border: 0px !important; height: 1px !important; width: 1px !important;">Hochspringen nach:</span>2,0]][[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-%3A1%202-1|2,1]][[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-%3A1%202-2|2,2]]</sup></span> <span class="reference-text" style="box-sizing: inherit;"><span class="ve-pasteprotect" style="box-sizing: inherit;">31. <span data-ve-attributes="{"style":"mso-tab-count:1"}" style="box-sizing: inherit;"> <span style="box-sizing: inherit;"> </span></span>Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter, AWMF-Registernummer: 030/089 [</span><span style="color: rgb(51, 51, 51)">https://www.awmf.org/leitlinien/detail/ll/030-089.html</span><span data-ve-attributes="{"style":"mso-ansi-language:DE"}" style="box-sizing: inherit;"><span class="ve-pasteprotect" style="box-sizing: inherit;"></span></span></span>
| |
| # <span class="mw-cite-backlink" style="box-sizing: inherit; user-select: none;">[[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-3|<span class="cite-accessibility-label" style="box-sizing: inherit; user-select: none; top: -99999px; clip: rect(1px, 1px, 1px, 1px); overflow: hidden; position: absolute !important; padding: 0px !important; border: 0px !important; height: 1px !important; width: 1px !important;">Hochspringen</span>↑]]</span> <span class="reference-text" style="box-sizing: inherit;"><span style="color: rgb(51, 51, 51)">32. <span class="ve-pasteprotect" style="box-sizing: inherit;"><span data-ve-attributes="{"style":"mso-tab-count:1"}" style="box-sizing: inherit;"> <span style="box-sizing: inherit;"> </span></span></span>Nau R, Blei C, Eiffert H: Intrathecal Antibacterial and Antifungal Therapies. Clin Microbiol Rev 2020; 33(3)</span></span>
| |
| # <span class="mw-cite-backlink" style="box-sizing: inherit; user-select: none;">[[DGI:Nosokomiale Ventrikulitis und Meningitis/Therapie#cite%20ref-4|<span class="cite-accessibility-label" style="box-sizing: inherit; user-select: none; top: -99999px; clip: rect(1px, 1px, 1px, 1px); overflow: hidden; position: absolute !important; padding: 0px !important; border: 0px !important; height: 1px !important; width: 1px !important;">Hochspringen</span>↑]]</span> <span class="reference-text" style="box-sizing: inherit;"><span style="color: rgb(51, 51, 51)">33. <span class="ve-pasteprotect" style="box-sizing: inherit;"><span data-ve-attributes="{"style":"mso-tab-count:1"}" style="box-sizing: inherit;"> <span style="box-sizing: inherit;"> </span></span></span>Karvouniaris M, Brotis AG, Tsiamalou P, Fountas KN: The Role of Intraventricular Antibiotics in the Treatment of Nosocomial Ventriculitis/Meningitis from Gram-Negative Pathogens: A Systematic Review and Meta-Analysis. World Neurosurg 2018; 120:e637-e650</span></span>
| |
Kalkulierte Therapie[1][2]
Vancomycin PLUS Meropenem
Alternative zum Meropenem: Ceftazidim oder Cefepim (in Anlehnung an das lokale in-vitro-Resistenzmuster). Cephalosporine penetrieren nicht-entzündlich veränderte Meningen relativ schlecht, daher empfehlen die Autor:innen bei empirischer Anwendung dieser Substanzen: Anwendung einer höheren Loading dose und ein TDM. (im Falle eines operativen Zugangs durch Schleimhäute PLUS Metronidazol)
Alternative Vancomycin: Linezolid (cave: bakteriostatisch)
- ↑ Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael Scheld W, van de Beek D, Bleck TP, Garton HJ, Zunt JR: 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017; 64: e34–e65
- ↑ Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis im Erwachsenenalter, AWMF-Registernummer: 030/089 [https://www.awmf.org/leitlinien/detail/ll/030-089.html